Harnessing disulfidptosis-ferroptosis synergy to potentiate radiotherapy in triple-negative breast cancer

Pharmacological targeting of FKBPL with rapamycin sensitizes triple-negative breast cancer to ferroptosis.

Triple-negative breast cancer (TNBC) remains a clinically formidable subtype, while resistant to conventional apoptotic cell death pathways, it exhibits a unique and exploitable vulnerability to ferroptosis. Here, we identify the FK506-binding protein-like (FKBPL) as a novel scaffold that dictates ferroptosis sensitivi...

CRISPR Nanomachinery-Sensitized Nanocatalytic Tumor Ferroptosis in Triple-Negative Breast Cancer.

The luminal androgen receptor (LAR) subtype of triple-negative breast cancer (TNBC) represents a formidable therapeutic challenge, necessitating sophisticated strategies that exploit unique tumor vulnerabilities. In the present work, we introduce a biomimetic nanotherapeutic that integrates single-atom iron nanocatalys...

PABPC1 dictates castration sensitivity in prostate cancer via orchestrating ferroptosis resistance and CD8(+) T-cell dysfunction.

Dual GPX4/PARP inhibitor YHD-26 exerts potent antitumor activity against triple-negative breast cancer via ferroptosis and DNA damage synergy.

Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, associated with poor prognosis and frequent drug resistance. Ferroptosis refers to an iron-dependent form of non-apoptotic cell death triggered by lipid peroxidation, offering a promising strategy to overcome this resistance. Her...

METTL3 Promotes the Growth of Triple-Negative Breast Cancer Cells by Modulating Ferroptosis-Related Oxidative Stress via the ELF1/GPX4 Axis.

A novel METTL3/ELF1/GPX4 axis through which METTL3 promotes TNBC growth by regulating oxidative stress and ferroptosis-related markers is suggested, providing a basis for further investigation of this pathway in the context of TNBC biology and therapeutic development.

Ferroptosis-driven radio-immunosensitization: an emerging mechanistic framework for enhancing response to immune checkpoint inhibitor therapy

Immune checkpoint inhibitors (ICIs) provide durable tumor control in some patients, but resistance can develop through tumor-intrinsic and microenvironmental mechanisms. This narrative review examines the metabolic and immune conditions under which ferroptosis may enhance ICI responsiveness or resensitize selected ICI-...